MU262 

MU262 is a MUS81 inhibitor with an IC₅₀ value of 0.87 μM. MU262 directly inhibits the catalytic activity of MUS81 without interfering with DNA binding, induces genomic instability in tumor cells, and specifically inhibits the HR/BIR repair pathway. The combination of MU262 with Cisplatin (HY-17394) significantly enhances the chemotherapeutic killing effect. MU262 serves as a chemical biology tool for studying MUS81 function, and also acts as a lead compound for the development of anticancer therapies that exploit DNA repair defects in cancer cells^[1].

MU262 (0.5-5 μM; 0-72 h) inhibits break-induced replication in U2OS BIR-GFP cells with an IC₅₀ of 1.53 μM^[1].
MU262 (1-5 μM; 0-72 h) inhibits homologous recombination in U2OS DR-GFP cells^[1].
MU262 (3-12 μM; 48 h) induces micronucleus formation in U2OS cells^[1].
MU262 (72 h) induces persistent DNA damage in U2OS cells, an effect detectable by increased formation of γH2AX foci^[1].
MU262 (administered for 10-12 days) reduces the clonogenic survival rate of U2OS cells^[1].
MU262 (2-16 μM; 96-120 h) acts synergistically with Cisplatin (HY-17394) to reduce the viability of U2OS cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

374.37

C₂₀H₁₅FN₆O

1846587-13-0

OC1=C(C2=NC3=CC=CC=C3N2)N=NC4=C(C5=CC=C(F)C=C5)C(CC)=NN41

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Prochazkova J, et al. Discovery of Two Structurally Distinct Classes of Inhibitors Targeting the Nuclease MUS81 and Enhancing Efficacy of Chemotherapy in Cancer Cells. J Med Chem. 2026;69(5):5350-5369.  [Content Brief]